These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 15372888)

  • 1. Preventing cardiovascular disease in diabetes.
    Harvey JN
    Clin Med (Lond); 2004; 4(4):311-4. PubMed ID: 15372888
    [No Abstract]   [Full Text] [Related]  

  • 2. Legacy effect in medicine-the expanding horizon!
    Wander GS; Bansal M
    Indian Heart J; 2018; 70(6):769-771. PubMed ID: 30580842
    [No Abstract]   [Full Text] [Related]  

  • 3. Diabetic cardiovascular disease lost in translation between endocrinology and cardiology.
    Dagdelen S
    Am J Cardiol; 2008 Oct; 102(8):1115-6. PubMed ID: 18929722
    [No Abstract]   [Full Text] [Related]  

  • 4. Cardiovascular Safety of Current and Emerging Glucose-Lowering Therapies.
    Fitchett D
    Can J Diabetes; 2015 Dec; 39 Suppl 5():S176-82. PubMed ID: 26654861
    [No Abstract]   [Full Text] [Related]  

  • 5. Diabetes as a 'cardiovascular disease equivalent': implications for treatment.
    Laakso M
    Nat Clin Pract Cardiovasc Med; 2008 Nov; 5(11):682-3. PubMed ID: 18797431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is glucose control important for prevention of cardiovascular disease in diabetes?
    Mannucci E; Dicembrini I; Lauria A; Pozzilli P
    Diabetes Care; 2013 Aug; 36 Suppl 2(Suppl 2):S259-63. PubMed ID: 23882055
    [No Abstract]   [Full Text] [Related]  

  • 7. Cardiovascular effects of some antidiabetic drugs.
    Med Lett Drugs Ther; 2017 Aug; 59(1527):136-138. PubMed ID: 28787745
    [No Abstract]   [Full Text] [Related]  

  • 8. [Possibilities of influencing cardiovascular risk in type 2 diabetes mellitus by antidiabetic treatment Lowering of cardiovascular risk in treatment with liraglutide - Results of the LEADER].
    Olšovský J
    Vnitr Lek; 2016; 62(7-8):613-5. PubMed ID: 27627086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does intensive glycemic control improve cardiovascular outcomes?
    Pendergrass M
    Nat Clin Pract Endocrinol Metab; 2008 Oct; 4(10):529. PubMed ID: 18806805
    [No Abstract]   [Full Text] [Related]  

  • 10. Intensive glycemic control and cardiovascular disease: an update.
    Brown A; Reynolds LR; Bruemmer D
    Nat Rev Cardiol; 2010 Jul; 7(7):369-75. PubMed ID: 20404853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Intensive blood glucose lowering to reduce cardiovascular risk: contra].
    Marx N
    Dtsch Med Wochenschr; 2009 May; 134(20):1061. PubMed ID: 19421930
    [No Abstract]   [Full Text] [Related]  

  • 12. [Intensive blood glucose lowering to reduce cardiovascular risk: pro].
    Martin S
    Dtsch Med Wochenschr; 2009 May; 134(20):1060. PubMed ID: 19421929
    [No Abstract]   [Full Text] [Related]  

  • 13. [Glitazones critically evaluated].
    Schernthaner G
    Dtsch Med Wochenschr; 2007 Dec; 132(49):2619. PubMed ID: 18050024
    [No Abstract]   [Full Text] [Related]  

  • 14. Incretins: cardiovascular safety and rationale for use.
    Kok A
    Cardiovasc J Afr; 2013 Mar; 24(2):46. PubMed ID: 23750348
    [No Abstract]   [Full Text] [Related]  

  • 15. [Improvement in cardiovascular prognosis of type 2 diabetes mellitus, is it a reality?].
    Ruiz-Hurtado G; Vigil L; Ruilope LM
    Hipertens Riesgo Vasc; 2016; 33(4):123-125. PubMed ID: 27770841
    [No Abstract]   [Full Text] [Related]  

  • 16. [A critical appraisal of the European guidelines on diabetes, pre-diabetes and cardiovascular diseases].
    Miccoli R
    G Ital Cardiol (Rome); 2014 Jun; 15(6):350-4. PubMed ID: 25072420
    [No Abstract]   [Full Text] [Related]  

  • 17. [New drugs for type 2 diabetes: expanding cardiovascular protection beyond type 2 diabetes?].
    Mannucci E
    G Ital Cardiol (Rome); 2012 Dec; 13(12 Suppl 1):3S. PubMed ID: 23258122
    [No Abstract]   [Full Text] [Related]  

  • 18. [Too positive comment on glitazones].
    Lindberg M
    Ugeskr Laeger; 2007 Feb; 169(8):733; author reply 733. PubMed ID: 17338040
    [No Abstract]   [Full Text] [Related]  

  • 19. Cardiovascular diseases and diabetes mellitus.
    Bandyopadhyay P
    Drug News Perspect; 2006; 19(6):369-75. PubMed ID: 16971974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SGLT2 inhibitors: providing cardiovascular protection in type 2 diabetes?
    Wilding J
    Lancet Diabetes Endocrinol; 2016 May; 4(5):379-81. PubMed ID: 27009624
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.